Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering GMP Work Plan Is One-Third Complete; Toughest Battles Lie Ahead

This article was originally published in The Tan Sheet

Executive Summary

The remaining two-thirds of Schering-Plough's GMP work plan contain the most challenging requirements under the company's 2002 manufacturing consent decree, CEO Fred Hassan told analysts Nov. 18

You may also be interested in...



Schering: Competitor Switch Of Rx Antihistamine, Nasal Steroid Anticipated

Schering-Plough expects the over-the-counter switch or generic availability of a competing Rx antihistamine or nasal steroid to impact its 2004 fiscal year earnings

Schering: Competitor Switch Of Rx Antihistamine, Nasal Steroid Anticipated

Schering-Plough expects the over-the-counter switch or generic availability of a competing Rx antihistamine or nasal steroid to impact its 2004 fiscal year earnings

Schering: Competitor Switch Of Rx Antihistamine, Nasal Steroid Anticipated

Schering-Plough expects the over-the-counter switch or generic availability of a competing Rx antihistamine or nasal steroid to impact its 2004 fiscal year earnings

Related Content

Topics

UsernamePublicRestriction

Register

PS096199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel